Impact of Obesity Interventions on Managed Care

Transcription

1 Established 1995 SUPPLEMENT Interventions on Managed Care Highlights n Obesity: Definition, Comorbidities, Causes, and Burden n Overweight and Obesity Management Strategies n The Role of Managed Care Organizations in Obesity Management n CE Sample Posttest Volume 22, Number 7, Supplement May 2016 Supplement to The American Journal of Managed Care 2016 Managed Care & Healthcare Communications, LLC

2 Interventions on Managed Care Release date: May 16, 2016 Expiration date: May 16, 2017 Estimated time to complete activity: 3.0 hours Type of activity: Application Medium: Print with Internet-based posttest, evaluation, and request for credit Fee: Free This activity is supported by educational grants from Novo Nordisk and Takeda Pharmaceuticals U.S.A., Inc. Intended Audience Managed care pharmacists. Activity Overview In the United States, obesity is characterized as this century s greatest healthcare threat. The American Medical Association and several other large organizations now classify obesity as a disease. The obesity epidemic is leading to advancements in the way obesity is treated in primary care. Behavioral therapy techniques provide a framework for discussing obesity in primary care. A number of factors either deter or stimulate the progress of weight-loss therapy. Communicating the benefits of losing weight for the management of comorbid conditions is a potent motivator for weight loss. Diet and exercise advice should be individualized to consider patient preferences, limitations, and ability. A team-based approach with participation of dieticians, nurse specialists, and obesity specialists, as well as commercial weight-loss programs, distributes the burden of management away from a single primary care clinician and provides patients with access to more treatment modalities. Obesity treatment options have increased dramatically in recent years, including new weight-loss drugs, bariatric surgery innovations, and minimally invasive intragastric balloons. The efficacy and tolerability of medications for long-term management, including orlistat, lorcaserin, phentermine-topiramate ER, and naltrexone-bupropion SR, are discussed, as well as the role of bariatric surgery and intragastric balloons. Managed care organizations are addressing changes in national requirements and are responding to the availability of new weight-loss drugs to help patients achieve better health. Statement of Educational Need Approximately one-third of American adults are obese. The high prevalence of obesity, the associated medical complications, and high healthcare costs make obesity a serious public health issue. Individuals who are extremely obese (having a body mass index [BMI] of kg/m 2 ) live an estimated 6.5 to 13.7 years less than people with a normal BMI. Obesity is a risk factor for numerous chronic diseases, including diabetes, heart disease, osteoarthritis, and cancer. In addition, obesity increases school absenteeism and decreases earning potential. Healthcare provider awareness may lead to increased screening of patients at risk, increased prescribing of medications to prevent or treat obesity, and recommendations of lifestyle changes for those who are obese. Educational Objectives Upon completion of this activity, participants should be able to: Explain the prevalence, incidence, and economic consequences of obesity. Examine current obesity treatment recommendations and discuss the role of pharmacologic options and lifestyle modifications in the management of obesity. Identify the economic impact of obesity from a long-term perspective. Demonstrate the importance of screening, lifestyle changes, and pharmacotherapy in treating and preventing obesity. Accreditation Statement Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 3.0 contact hours (0.3 CEUs) under the ACPE universal activity number H01-P. The activity is available for CE credit through May 16, Obtaining Credit: Participants must read the article, complete the online posttest and achieve a passing score of 70% or higher, and complete an online evaluation and request for credit. Detailed instructions on obtaining CE credit are included at the end of this activity. This CE activity is also offered free online at and at where you will be directed to the activity in its entirety, including the online pretest and posttest, activity evaluation, and request for credit. Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements. n THE AMERICAN JOURNAL OF MANAGED CARE n

3 Publishing Staff Senior Vice President of Operations and Clinical Affairs Jeff D. Prescott, PharmD, RPh Senior Clinical Projects Manager Ida Delmendo Clinical Projects Manager Cindy Spielvogel Project Manager Jessica Toye Proofreaders Griselda Demassey Maggie Shaw Associate Editor Jeanne Linke Assistant Editor Sarah Anwar Clinical Editor Michael R. Page, PharmD, RPh Designer Julianne Costello Associate Publisher Justin T. Gallagher Director of Sales Sara Belanger National Account Managers Gabrielle Consola Michael Costella Corporate Chairman and CEO Mike Hennessy, Sr Vice Chairman Jack Lepping President Mike Hennessy, Jr Chief Operating Officer/CFO Neil Glasser, CPA/CFE President, Managed Markets, Pharmacy, and Rare Disease Brian Haug Executive Vice President and General Manager John Maglione Chief Creative Officer Jeff Brown Human Resources Director Shari Lundenberg President, Pharmacy Times Continuing Education David Heckard Copyright 2016 by Managed Care & Healthcare Communications, LLC May 2016 Vol. 22, No. 7, Sup. Interventions on Managed Care Table of Contents Participating Faculty Reports Obesity: Definition, Comorbidities, Causes, and Burden Caroline M. Apovian, MD, FACP, FACN Overweight and Obesity Management Strategies Scott Kahan, MD, MPH The Role of Managed Care Organizations in Obesity Management Kenneth L. Schaecher, MD, FACP, CPC CE Sample Posttest S174 S176 S186 S197 S209 A Supplement to The American Journal of Managed Care PROJ ACE0042 VOL. 22, NO. 7 n THE AMERICAN JOURNAL OF MANAGED CARE n S173

4 n PARTICIPATING FACULTY n Interventions on Managed Care This supplement to The American Journal of Managed Care includes a review of the prevalence and economic consequences of obesity. Potential causes and comorbidities associated with obesity are also discussed. Potential treatment options, from diet and exercise to bariatric surgery, will be highlighted, and various strategies that managed care organizations can utilize to help patients better manage their obesity will be discussed. n Faculty Caroline M. Apovian, MD, FACP, FACN Director Nutrition and Weight Management Center Boston Medical Center Professor of Medicine and Pediatrics Boston University School of Medicine Boston, Massachusetts Scott Kahan, MD, MPH Medical Director Strategies to Overcome and Prevent (STOP) Obesity Alliance George Washington University Director National Center for Weight and Wellness Washington, DC Kenneth L. Schaecher, MD, FACP, CPC Medical Director SelectHealth Salt Lake City, Utah n Editorial Support Jill E. Allen, PharmD Drug Information Consultant Pin Oak Associates Salt Lake City, Utah Christine Sokoloski, MS Medical Writer Hillsborough, New Jersey Jeannette Y. Wick, RPh, MBA, FASCP Visiting Professor University of Connecticut School of Pharmacy Storrs, Connecticut n Faculty Disclosures Caroline M. Apovian, MD, FACP, FACN, has the following relevant financial relationships with commercial interests to disclose: Consultant: Amylin, Arena, EnteroMedics, Gelesis, Johnson and Johnson, Merck, Novo Nordisk, Nutrisystem, Orexigen, Sanofi-Aventis, Scientific Intake, Takeda, Zafgen Research Funding: Amylin, Aspire Bariatrics, the Dr. Robert C. and Veronica Atkins Foundation, GI Dynamics, Lilly, MetaProteomics, MYOS Corporation, Orexigen, Pfizer, Sanofi-Aventis Stock: Science Smart LLC S174 n n MAY 2016

5 n PARTICIPATING FACULTY n Scott Kahan, MD, MPH, has the following relevant financial relationships with commercial interests to disclose: Board Membership: American Board of Obesity Medicine Consultant: Novo Nordisk, Orexigen, Takeda, Vivus Kenneth L. Schaecher, MD, FACP, CPC, has no relevant financial relationships with commercial interests to disclose. n Editorial Support Disclosures Jill E. Allen, PharmD; Christine Sokoloski, MS; and Jeannette Wick, RPh, MBA, FASCP, have no relevant financial relationships with commercial interests to disclose. The American Journal of Managed Care Publishing Staff Jeff D. Prescott, PharmD, RPh; Ida Delmendo; and Cindy Spielvogel have no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education Planning Staff Dave Heckard; Maryjo Dixon, RPh; Dipti Desai, PharmD, RPh; Beatriz Manzor Mitrzyk, PharmD, BCPS; Donna Fausak; Nathalie Harden; and Tara DeLorenzo have no relevant financial relationships with commercial interests to disclose. Disclosure Policy According to the disclosure policy of The American Journal of Managed Care and Pharmacy Times Continuing Education, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. Disclosure of Unapproved/Off-Label Use The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care, Pharmacy Times Continuing Education, or any of the companies that provided commercial support for this CE activity. Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey. VOL. 22, NO. 7 n THE AMERICAN JOURNAL OF MANAGED CARE n S175